WPD and CNS to initiate Phase I clinical trial for Berubicin in pediatric brain cancer. Credit: Nephron.

WPD Pharmaceuticals and CNS Pharmaceuticals are set to initiate a Phase I clinical trial for Berubicin, an anthracycline, in paediatric brain cancer at the Children’s Memorial Health Institute in Poland.

The companies are currently working with experts at the institute to complete documentation for the upcoming study and scientific advice meeting.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

WPD and CNS also signed a sublicense agreement, which saw WPD receive commercial rights in a limited territory to Berubicin, including research and development.

The company subsequently secured a grant of $6m from the EU/Polish National Center for research and development.

These funds will be used for the upcoming Phase I trial. CNS is also fully supporting WPD to execute these studies.

WPD Pharmaceuticals CEO Mariusz Olejniczak said: “We look forward our collaboration with CNS and Children’s Memorial in Poland to initiate what we believe to be the first investigation of a unique topoisomerase II inhibitor that appears to be able to cross the blood-brain barrier in paediatric brain tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We will continue to drive the clinical development of Berubicin in the upcoming Phase II trial in adult patients.”

Treatment of brain cancer patients with Berubicin is believed to have demonstrated positive responses that include one durable complete response in Phase I human clinical trial conducted by Reata.

Four of WPD’s ten novel drug candidates are currently in the clinical development stage. These drug candidates were researched at MD Anderson Cancer Center, Mayo Clinic, and Emory University.

The company currently has ongoing collaborations with Wake Forest University, as well as hospitals and academic centres in Poland.